PMID: 18423135Apr 22, 2008Paper

Anti-angiogenesis targeting drugs: a review

Ai zheng = Aizheng = Chinese journal of cancer
Ka Jia, Jin Li

Abstract

The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for cancer therapy. One of the key mediators of angiogenesis is vascular endothelial growth factor (VEGF), which is an appealing target for anticancer therapy. The development of anti-VEGF/VEGFR agents and the latest clinical data are reviewed, including bevacizumab as a monoclonal antibody to VEGF, sunitinib and sorafenib as VEGFR tyrosine kinase inhibitors, and IMC-1C11 as VEGFR monoclonal antibody.

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Breast Cancer Research : BCR
Dorte Lisbet NielsenClaus Kamby
Microcirculation : the Official Journal of the Microcirculatory Society, Inc
Robin J Young, Malcolm W R Reed
Proceedings of the American Thoracic Society
Leora Horn, Alan B Sandler
© 2022 Meta ULC. All rights reserved